ArticleNeuro-oncology2023

The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.

Atsushi Natsume et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.